111 (NASDAQ:YI) Given “Sell (E+)” Rating at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 111 (NASDAQ:YI) in a report issued on Thursday morning,Weiss Ratings reports.

111 Stock Up 1.3 %

YI stock opened at $8.53 on Thursday. The firm has a market capitalization of $72.95 million, a PE ratio of -2.13 and a beta of 0.57. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The stock’s 50 day moving average is $8.35 and its 200-day moving average is $7.46.

111 (NASDAQ:YI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $527.14 million during the quarter.

Hedge Funds Weigh In On 111

Several institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. increased its holdings in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd bought a new position in shares of 111 during the 4th quarter valued at approximately $245,000. Finally, FIL Ltd purchased a new stake in shares of 111 during the 4th quarter worth approximately $450,000. 21.32% of the stock is owned by institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.